ArticleJACC. Case reports2025
Vitamin C Deficiency as a Readily Reversible Cause of Pulmonary Hypertension.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Are the UK's vitamin C recommendations evidence-based? A critical comment.The British journal of nutrition · 2026Review
- A Rare Case of Reversible Pulmonary Hypertension Phenotype in a Child with Scurvy: Aetiologies Insights.Reports (MDPI) · 2026Article
- Reversible pulmonary hypertension in a patient diagnosed with scurvy.BMJ case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) has a diverse range of etiologies and carries significant morbidity and mortality. Here, we describe a case of reversible PAH caused by scurvy. A 45-year-old woman presented with shortness of breath and was found to be in acute right heart failure owing to PAH. Physical examination demonstrated features of scurvy. She initially required vasopressors, supplemental oxygen therapy, and PAH therapies, but rapidly improved with vitamin C supplementation. Vitamin C plays a role in the nitric oxide pathway targeted by most PAH approved agents and others involved in pulmonary vascular modulation such as hypoxia inducible factor regulation, representing a rare cause of PAH. Clinical scurvy is uncommon but can present as reversible PAH and right-sided heart failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.